![]() |
Celldex Therapeutics Presents Positive Results From Phase 2 Study Of The Antibody-Dru
Celldex Therapeutics, Inc. (NASDAQ: CLDX) announced the results of a positive Phase 2 study of CDX-011 (formerly CR011-vcMMAE), in patients with heavily pre-treated, locally advanced or metastatic breast cancers...
More... |
| All times are GMT -7. The time now is 11:01 AM. |
Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2026, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021